Search Results - "LEWIS, V. Ann"

Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction by Summerfield, Scott G, Read, Kevin, Begley, David J, Obradovic, Tanja, Hidalgo, Ismael J, Coggon, Sara, Lewis, Ann V, Porter, Rod A, Jeffrey, Phil

“…The dispositions of 50 marketed central nervous system (CNS) drugs into the brain have been examined in terms of their rat in situ (P) and in vitro apparent…”
Get more information

The identification of clinical candidate SB-480848 : A potent inhibitor of lipoprotein-associated phospholipase A2 by BLACKIE, Josie A, BLOOMER, Jackie C, MILLINER, Kevin J, MOORES, Kitty E, PINTO, Ivan L, SMITH, Stephen A, STANSFIELD, Ian G, STANWAY, Steven J, TAYLOR, Maxine A, THEOBALD, Colin J, BROWN, Murray J. B, CHENG, Hung-Yuan, HAMMOND, Beverley, HICKEY, Deirdre M. B, IFE, Robert J, LEACH, Colin A, LEWIS, V. Ann, MACPHEE, Colin H

“…Modification of the pyrimidone 5-substituent in clinical candidate SB-435495 has given a series of inhibitors of recombinant lipoprotein-associated…”
Get full text

The discovery of SB-435495: A potent, orally active inhibitor of lipoprotein-associated phospholipase A2 for evaluation in man by BLACKIE, Josie A, BLOOMER, Jackie C, MACPHEE, Colin H, MILLINER, Kevin J, MOORES, Kitty E, PINTO, Ivan L, SMITH, Stephen A, STANSFIELD, Ian G, STANWAY, Steven J, TAYLOR, Maxine A, THEOBALD, Colin J, WHITTAKER, Caroline M, BROWN, Murray J. B, CHENG, Hung-Yuan, ELLIOTT, Richard L, HAMMOND, Beverley, HICKEY, Deirdre M. B, IFE, Robert J, LEACH, Colin A, LEWIS, V. Ann

Get full text

Characterisation of SB-221420-A - a neuronal Ca(2+) and Na(+) channel antagonist in experimental models of stroke by Campbell, C A, Barone, F C, Benham, C D, Hadingham, S J, Harries, M H, Harling, J D, Hills, J M, Lewis, V A, Mackay, K B, Orlek, B S, White, R F, Parsons, A A, Hunter, A J

“…For progression to clinical trials in stroke, putative neuroprotective compounds should show robust efficacy post-ischaemia in several experimental models of…”
Get full text

The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man by Blackie, Josie A, Bloomer, Jackie C, Brown, Murray J B, Cheng, Hung-Yuan, Elliott, Richard L, Hammond, Beverley, Hickey, Deirdre M B, Ife, Robert J, Leach, Colin A, Lewis, V Ann, Macphee, Colin H, Milliner, Kevin J, Moores, Kitty E, Pinto, Ivan L, Smith, Stephen A, Stansfield, Ian G, Stanway, Steven J, Taylor, Maxine A, Theobald, Colin J, Whittaker, Caroline M

“…The introduction of a functionalised amido substituent into a series of 1-(biphenylmethylacetamido)-pyrimidones has given a series of inhibitors of recombinant…”
Get full text

The identification of a potent, water soluble inhibitor of lipoprotein-associated phospholipase A2 by BOYD, Helen F, HAMMOND, Beverley, STANSFIELD, Ian G, THEOBALD, Colin J, WHITTAKER, Caroline M, HICKEY, Deirdre M. B, IFE, Robert J, LEACH, Colin A, LEWIS, V. Ann, MACPHEE, Colin H, MILLINER, Kevin J, PINTO, Ivan L, SMITH, Stephen A

“…Modification of the pyrimidone 5-substituent in a series of 1-((amidolinked)-alkyl)-pyrimidones, lipophilic inhibitors of lipoprotein-associated phospholipase…”
Get full text

Comparison of the cardiovascular effects of the novel 5-HT(1B/1D) receptor agonist, SB 209509 (VML251), and sumatriptan in dogs by Parsons, A A, Parker, S G, Raval, P, Campbell, C A, Lewis, V A, Griffiths, R, Hunter, A J, Hamilton, T C, King, F D

“…The systemic cardiovascular effects of a novel 5-hydroxtryptamine (5-HT)(1B/1D)-receptor agonist were investigated in the anaesthetised dog. SB 209509 (VML…”
Get full text

Comparison of the Cardiovascular Effects of the Novel 5-HT1B/1D Receptor Agonist, SB 209509 (VML251), and Sumatriptan in Dogs by Parsons, Andrew A, Parker, Stephen G, Raval, Pravin, Campbell, Colin A, Lewis, V. Ann, Griffiths, Robin, Hunter, A Jackie, Hamilton, Thomas C, King, Frank D

“…The systemic cardiovascular effects of a novel 5-hydroxtryptamine (5-HT)1B/1D-receptor agonist were investigated in the anaesthetised dog. SB 209509 (VML 251)…”
Get full text